scholarly journals Optimizing aminoglycoside dosing regimens for critically-ill pediatric patients with augmented renal clearance: a convergence of parametric and non-parametric population approaches

Author(s):  
Sean N. Avedissian ◽  
Roxane Rohani ◽  
John Bradley ◽  
Jennifer Le ◽  
Nathaniel J. Rhodes

Objective: Augmented renal clearance (ARC) can occur in critically-ill pediatric patients receiving aminoglycosides such as gentamicin and tobramycin, yet optimal dosing strategies for ARC are undefined. We evaluated the probability of achieving efficacious or toxic exposures in pediatrics. Methods: Parallel population modeling of concentration strategies were pursued using Pmetrics v1.5.2 (non-parametric) and Monolix v2019R2 (parametric). Bayesian exposures were used to classify ARC based on total CL. The effect of SCR, CRCL, TBW, post-natal age (PNA), and ARC were explored as covariates. Probabilities of target attainment (PTA) (i.e., Cmax/MIC, AUC:MIC) and of toxic exposure (PTE) (i.e., Cmin>2 mcg/mL) were calculated according to PNA and ARC. Results: 123 patients (1-21yrs, 56%female) contributed 304 concentrations. A two-compartment was superior to a one-compartment model in both approaches. Bayesian posterior predicted concentrations from the non-parametric base model fitted the data well (R2=0.96) and classified 34 patients as having ARC (28%). Both the non-parametric and parametric approaches resulted in allometrically scaling of TBW on V and CL. ARC modified CL and central V. CRCL and a maturation function modified CL. ARC was associated with a 1.49- vs. 1.66-fold increase in CL and a 1.56- vs 1.66-fold increase in the central V (non-parametric vs. parametric). High dose of 12 mg/kg/day was required to achieve adequate PTA when MIC were 1-2 mcg/mL; ARC lowered achievable MICs. When PNA< 2 years, PTE was increased. Conclusions: Aminoglycoside monotherapy should be avoided in critically-ill pediatric patients with ARC when MICs exceed 1 mcg/mL, as optimal exposures are unachievable with standard dosing.

2017 ◽  
Vol 18 (9) ◽  
pp. 901-902 ◽  
Author(s):  
John N. van den Anker ◽  
Catherijne A. J. Knibbe ◽  
Dick Tibboel

2017 ◽  
Vol 18 (9) ◽  
pp. e388-e394 ◽  
Author(s):  
Sean N. Avedissian ◽  
Erin Bradley ◽  
Diana Zhang ◽  
John S. Bradley ◽  
Lama H. Nazer ◽  
...  

2015 ◽  
Vol 59 (11) ◽  
pp. 7027-7035 ◽  
Author(s):  
Pieter A. J. G. De Cock ◽  
Joseph F. Standing ◽  
Charlotte I. S. Barker ◽  
Annick de Jaeger ◽  
Evelyn Dhont ◽  
...  

ABSTRACTThere is little data available to guide amoxicillin-clavulanic acid dosing in critically ill children. The primary objective of this study was to investigate the pharmacokinetics of both compounds in this pediatric subpopulation. Patients admitted to the pediatric intensive care unit (ICU) in whom intravenous amoxicillin-clavulanic acid was indicated (25 to 35 mg/kg of body weight every 6 h) were enrolled. Population pharmacokinetic analysis was conducted, and the clinical outcome was documented. A total of 325 and 151 blood samples were collected from 50 patients (median age, 2.58 years; age range, 1 month to 15 years) treated with amoxicillin and clavulanic acid, respectively. A three-compartment model for amoxicillin and a two-compartment model for clavulanic acid best described the data, in which allometric weight scaling and maturation functions were addeda priorito scale for size and age. In addition, plasma cystatin C and concomitant treatment with vasopressors were identified to have a significant influence on amoxicillin clearance. The typical population values of clearance for amoxicillin and clavulanic acid were 17.97 liters/h/70 kg and 12.20 liters/h/70 kg, respectively. In 32% of the treated patients, amoxicillin-clavulanic acid therapy was stopped prematurely due to clinical failure, and the patient was switched to broader-spectrum antibiotic treatment. Monte Carlo simulations demonstrated that four-hourly dosing of 25 mg/kg was required to achieve the therapeutic target for both amoxicillin and clavulanic acid. For patients with augmented renal function, a 1-h infusion was preferable to bolus dosing. Current published dosing regimens result in subtherapeutic concentrations in the early period of sepsis due to augmented renal clearance, which risks clinical failure in critically ill children, and therefore need to be updated. (This study has been registered at Clinicaltrials.gov as an observational study [NCT02456974].)


Antibiotics ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 612
Author(s):  
Annabel Werumeus Buning ◽  
Caspar J. Hodiamont ◽  
Natalia M. Lechner ◽  
Margriet Schokkin ◽  
Paul W. G. Elbers ◽  
...  

Altered pharmacokinetics (PK) of hydrophilic antibiotics in critically ill patients is common, with possible consequences for efficacy and resistance. We aimed to describe ceftazidime population PK in critically ill patients with a proven or suspected Pseudomonas aeruginosa infection and to establish optimal dosing. Blood samples were collected for ceftazidime concentration measurement. A population PK model was constructed, and probability of target attainment (PTA) was assessed for targets 100% T > MIC and 100% T > 4 × MIC in the first 24 h. Ninety-six patients yielded 368 ceftazidime concentrations. In a one-compartment model, variability in ceftazidime clearance (CL) showed association with CVVH. For patients not receiving CVVH, variability in ceftazidime CL was 103.4% and showed positive associations with creatinine clearance and with the comorbidities hematologic malignancy, trauma or head injury, explaining 65.2% of variability. For patients treated for at least 24 h and assuming a worst-case MIC of 8 mg/L, PTA was 77% for 100% T > MIC and 14% for 100% T > 4 × MIC. Patients receiving loading doses before continuous infusion demonstrated higher PTA than patients who did not (100% T > MIC: 95% (n = 65) vs. 13% (n = 15); p < 0.001 and 100% T > 4 × MIC: 20% vs. 0%; p = 0.058). The considerable IIV in ceftazidime PK in ICU patients could largely be explained by renal function, CVVH use and several comorbidities. Critically ill patients are at risk for underexposure to ceftazidime when empirically aiming for the breakpoint MIC for P. aeruginosa. A loading dose is recommended.


2018 ◽  
Vol 57 (9) ◽  
pp. 1107-1121 ◽  
Author(s):  
Idoia Bilbao-Meseguer ◽  
Alicia Rodríguez-Gascón ◽  
Helena Barrasa ◽  
Arantxazu Isla ◽  
María Ángeles Solinís

2012 ◽  
Vol 46 (7-8) ◽  
pp. 952-959 ◽  
Author(s):  
Veerle Grootaert ◽  
Ludo Willems ◽  
Yves Debaveye ◽  
Geert Meyfroidt ◽  
Isabel Spriet

Sign in / Sign up

Export Citation Format

Share Document